Skip to main content
Top
Published in: Rheumatology International 10/2019

Open Access 01-10-2019 | Giant Cell Arteritis | Observational Research

Characteristics of patients with giant cell arteritis who experience visual symptoms

Authors: Chung Shen Chean, James A. Prior, Toby Helliwell, John Belcher, Sarah L. Mackie, Samantha L. Hider, Jennifer Liddle, Christian D. Mallen

Published in: Rheumatology International | Issue 10/2019

Login to get access

Abstract

Permanent vision loss is one of the most serious complications of giant cell arteritis (GCA) and therefore prompt diagnosis is paramount. However, diagnosis of GCA remains challenging due to its frequently non-specific presentation. Our aim was to identify differences in the characteristics of GCA patients with, and without, current visual symptoms. A cross-sectional survey was mailed to patients with a GCA Read code entered in their GP electronic medical record. Responders were categorised as those currently reporting a visual symptom or not. We compared general and GCA-specific characteristics in these two groups. The association of diagnostic delay with subsequent experience of visual symptoms was examined using unadjusted and adjusted linear regression analysis. 318 GCA patients responded to the survey (59.6%). Responders were predominantly female (69.8%), with a mean age of 73.7 years (SD 8.2). 28% reported current visual symptoms. There was no statistically significant difference in the general characteristics between those with and without visual symptoms. Of GCA-specific characteristics, pre-GCA diagnosis of diplopia (p = 0.018), temporary (p ≤ 0.001) or permanent visual problems (p = 0.001) and hoarseness (p = 0.004) were more common among those reporting current visual symptoms. There was no association between the extent of diagnostic delay and reporting of current visual symptoms. Though we found few characteristics to distinguish between GCA patients with or without current visual symptoms, diagnostic delay was not associated with current visual symptoms. Our findings highlighted the continued difficulty for clinicians to identify GCA patients at the highest risk of visual complications.
Appendix
Available only for authorised users
Literature
1.
go back to reference Petri H, Nevitt A, Sarsour K et al (2015) Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities. Arthritis Care Res (Hoboken) 67(3):390–395CrossRef Petri H, Nevitt A, Sarsour K et al (2015) Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities. Arthritis Care Res (Hoboken) 67(3):390–395CrossRef
2.
go back to reference Vodopivec I, Rizzo JF III (2018) Ophthalmic manifestations of giant cell arteritis. Rheumatology 57(suppl_2):ii72CrossRef Vodopivec I, Rizzo JF III (2018) Ophthalmic manifestations of giant cell arteritis. Rheumatology 57(suppl_2):ii72CrossRef
4.
go back to reference Figus M, Talarico R, D’Ascanio A et al (2013) Ocular involvement in giant cell arteritis. Clin Exp Rheumatol 31(1 Suppl 75):S96PubMed Figus M, Talarico R, D’Ascanio A et al (2013) Ocular involvement in giant cell arteritis. Clin Exp Rheumatol 31(1 Suppl 75):S96PubMed
5.
go back to reference Hayreh SS, Podhajsky PA, Zimmerman B (1998) Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 125(4):521–526CrossRefPubMed Hayreh SS, Podhajsky PA, Zimmerman B (1998) Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 125(4):521–526CrossRefPubMed
6.
go back to reference Dasgupta B, Borg FA, Hassan N et al (2010) BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology 49(8):1594–1597CrossRefPubMed Dasgupta B, Borg FA, Hassan N et al (2010) BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology 49(8):1594–1597CrossRefPubMed
7.
go back to reference Ezeonyeji AN, Borg FA, Dasgupta B (2011) Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clin Rheumatol 30(2):259–262CrossRefPubMed Ezeonyeji AN, Borg FA, Dasgupta B (2011) Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clin Rheumatol 30(2):259–262CrossRefPubMed
8.
go back to reference van der Geest Kornelis SM, Sandovici M, van Sleen Y et al (2018) What is the current evidence for disease subsets in giant cell arteritis? Arthritis Rheumatol 70(9):1366–1376CrossRefPubMedPubMedCentral van der Geest Kornelis SM, Sandovici M, van Sleen Y et al (2018) What is the current evidence for disease subsets in giant cell arteritis? Arthritis Rheumatol 70(9):1366–1376CrossRefPubMedPubMedCentral
9.
10.
go back to reference Patil P, Williams M, Maw WW et al (2015) Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol 33(2 Suppl 89):6 Patil P, Williams M, Maw WW et al (2015) Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol 33(2 Suppl 89):6
12.
go back to reference Ware J Jr, Kosinski M, Keller SD (1996) A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 34(3):220–233CrossRefPubMed Ware J Jr, Kosinski M, Keller SD (1996) A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 34(3):220–233CrossRefPubMed
13.
go back to reference Spitzer RL, Kroenke K, Williams J et al (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166:1092–1097CrossRefPubMed Spitzer RL, Kroenke K, Williams J et al (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166:1092–1097CrossRefPubMed
15.
go back to reference Kishimoto F, Ohtsuki H (2012) Comparison of VF-14 scores among different ophthalmic surgical interventions. Acta Med Okayama 66(2):101–110PubMed Kishimoto F, Ohtsuki H (2012) Comparison of VF-14 scores among different ophthalmic surgical interventions. Acta Med Okayama 66(2):101–110PubMed
16.
go back to reference Efron B, Tibshirani RJ (1994) An introduction to the bootstrap. CRC Press, London Efron B, Tibshirani RJ (1994) An introduction to the bootstrap. CRC Press, London
17.
go back to reference Singh AG, Kermani TA, Crowson CS et al (2015) Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol 42(2):309–315CrossRefPubMed Singh AG, Kermani TA, Crowson CS et al (2015) Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol 42(2):309–315CrossRefPubMed
18.
go back to reference Salvarani C, Cimino L, Macchioni P et al (2005) Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 53(2):293–297CrossRefPubMed Salvarani C, Cimino L, Macchioni P et al (2005) Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 53(2):293–297CrossRefPubMed
19.
go back to reference Liozon E, Herrmann F, Ly K et al (2001) Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 111(3):211–217CrossRefPubMed Liozon E, Herrmann F, Ly K et al (2001) Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 111(3):211–217CrossRefPubMed
20.
go back to reference González-Gay MA, García-Porrúa C, Llorca J et al (2000) Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine 79(5):283–292CrossRefPubMed González-Gay MA, García-Porrúa C, Llorca J et al (2000) Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine 79(5):283–292CrossRefPubMed
21.
go back to reference Bengtsson BA, Malmvall BE (1981) The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum 24(7):899–904CrossRefPubMed Bengtsson BA, Malmvall BE (1981) The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum 24(7):899–904CrossRefPubMed
22.
go back to reference Ji J, Dimitrijevic I, Sundquist J et al (2017) Risk of ocular manifestations in patients with giant cell arteritis: a nationwide study in Sweden. Scand J Rheumatol 46(6):484–489CrossRefPubMed Ji J, Dimitrijevic I, Sundquist J et al (2017) Risk of ocular manifestations in patients with giant cell arteritis: a nationwide study in Sweden. Scand J Rheumatol 46(6):484–489CrossRefPubMed
23.
go back to reference Liddle J, Bartlam R, Mallen CD et al (2017) What is the impact of giant cell arteritis on patients’ lives? A UK qualitative study. BMJ Open 7(8):e017073CrossRefPubMedPubMedCentral Liddle J, Bartlam R, Mallen CD et al (2017) What is the impact of giant cell arteritis on patients’ lives? A UK qualitative study. BMJ Open 7(8):e017073CrossRefPubMedPubMedCentral
24.
go back to reference Jobard S, Magnant J, Blasco H et al (2017) Quality of life of patients treated for giant cell arteritis: a case-control study. Clin Rheumatol 36(9):2055–2062CrossRefPubMed Jobard S, Magnant J, Blasco H et al (2017) Quality of life of patients treated for giant cell arteritis: a case-control study. Clin Rheumatol 36(9):2055–2062CrossRefPubMed
25.
go back to reference Kupersmith MJ, Speira R, Langer R et al (2001) Visual function and quality of life among patients with giant cell (temporal) arteritis. J Neuroophthalmol 21(4):266–273CrossRefPubMed Kupersmith MJ, Speira R, Langer R et al (2001) Visual function and quality of life among patients with giant cell (temporal) arteritis. J Neuroophthalmol 21(4):266–273CrossRefPubMed
26.
go back to reference Steinberg EP, Tielsch JM, Schein OD et al (1994) The VF-14: an index of functional impairment in patients with cataract. Arch Ophthalmol 112(5):630–638CrossRefPubMed Steinberg EP, Tielsch JM, Schein OD et al (1994) The VF-14: an index of functional impairment in patients with cataract. Arch Ophthalmol 112(5):630–638CrossRefPubMed
27.
go back to reference Valderas JM, Alonso J, Prieto L et al (2004) Content-based interpretation aids for health-related quality of life measures in clinical practice. An example for the visual function index (VF-14). Qual Life Res 13(1):35–44CrossRefPubMed Valderas JM, Alonso J, Prieto L et al (2004) Content-based interpretation aids for health-related quality of life measures in clinical practice. An example for the visual function index (VF-14). Qual Life Res 13(1):35–44CrossRefPubMed
28.
go back to reference Larson TS, Hall S, Hepper N et al (1984) Respiratory tract symptoms as a clue to giant cell arteritis. Ann Intern Med 101(5):594–597CrossRefPubMed Larson TS, Hall S, Hepper N et al (1984) Respiratory tract symptoms as a clue to giant cell arteritis. Ann Intern Med 101(5):594–597CrossRefPubMed
30.
go back to reference Saleh M, Turesson C, Englund M et al (2016) Visual complications in patients with biopsy-proven giant cell arteritis: a population-based study. J Rheumatol 43(8):1559–1565CrossRefPubMedPubMedCentral Saleh M, Turesson C, Englund M et al (2016) Visual complications in patients with biopsy-proven giant cell arteritis: a population-based study. J Rheumatol 43(8):1559–1565CrossRefPubMedPubMedCentral
31.
go back to reference Berger CT, Wolbers M, Meyer P et al (2009) High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology 48(3):258–261CrossRefPubMed Berger CT, Wolbers M, Meyer P et al (2009) High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology 48(3):258–261CrossRefPubMed
Metadata
Title
Characteristics of patients with giant cell arteritis who experience visual symptoms
Authors
Chung Shen Chean
James A. Prior
Toby Helliwell
John Belcher
Sarah L. Mackie
Samantha L. Hider
Jennifer Liddle
Christian D. Mallen
Publication date
01-10-2019
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 10/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04422-5

Other articles of this Issue 10/2019

Rheumatology International 10/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.